Disparities in Women with Heart Failure
- 54 Downloads
Despite comprising over half of the heart failure population, women have been under-represented in most major clinical heart failure trials. Women with heart failure are more likely to have a preserved systolic function, be older compared to men, and are more likely to have hypertension, diabetes, and obesity as the etiology of their heart failure. Furthermore, overall survival is better for women. These factors suggest that the disease process in women is not entirely the same as in men, and perhaps should not be treated the same. However, given the lack of prospective large number trials looking specifically at women and heart failure, there have been no statistically significant data to support tailoring medical therapy differently between men and women.
KeywordsWomen Heart failure Gender differences in heart failure
Hector O. Ventura has received honoraria from Gilead and Actelion. Ileana Pina has received consulting fees from GE Health, the US Food and Drug Administration, and Solvay. She has received honoraria from AstraZeneca, Novartis, and Otsuka. Somya A. Chandrasekaran and Carl J. Lavie report no potential conflicts of interest relevant to this article.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.• Pina, IL, Hsich, EM. Heart failure in women: a need for prospective data. J Am Coll Cardiology. 2009;42:491–7. This review is an excellent synopsis of major heart failure trials and women, and it highlights the difficulty in extrapolating data from women in heart failure trials.Google Scholar
- 10.Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification with V-type natriuretic peptide levels in patients with acute dyspnea:insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol. 2006;48:1808–12.PubMedCrossRefGoogle Scholar
- 18.Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian Enalapril Survival Study. The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429–35.Google Scholar
- 20.Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–38.PubMedCrossRefGoogle Scholar
- 21.Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.Google Scholar
- 25.Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm; evidence of gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29:1074–80.PubMedCrossRefGoogle Scholar
- 28.Lavie CJ, Milano RV, Ventura HO, et al. Peak oxygen consumption and heart failure prognosis in women. J Am Coll Cardiol. 2007;36:2237–42.Google Scholar
- 34.• Slaughter, MS, Rogers, JG, Milano, CA, et al. Advanced Heart Failure Treated with Continuous Flow Left Ventricular Assist Devices. N Engl J Med. 2009;361:2241–51. With the development and advances in mechanical device therapies for heart failure and observational data regarding complications and limitations, there are differences seen in the complications which arise for women with LVADs compared to men, and with the development of smaller devices the hope is that more women will be suitable candidates for LVADs and therefore more prospective data will be obtained.PubMedCrossRefGoogle Scholar